Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail

por Mohamed, Mohamed‐Eslam F., Feng, Tian, Enejosa, Jeffrey V., Fisniku, Ogert, Othman, Ahmed A.
Publicado 2019

Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate

por Mohamed, Mohamed‐Eslam F., Minocha, Mukul, Trueman, Sheryl, Feng, Tian, Enejosa, Jeffrey, Fisniku, Ogert, Othman, Ahmed A.
Publicado 2020

Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE

por Strand, Vibeke, Tundia, Namita, Bergman, Martin, Ostor, Andrew, Durez, Patrick, Song, In-Ho, Enejosa, Jeffrey, Schlacher, Casey, Song, Yan, Fleischmann, Roy
Publicado 2021

A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus

por Thompson, Melanie, Saag, Michael, DeJesus, Edwin, Gathe, Joseph, Lalezari, Jay, Landay, Alan L., Cade, Jerry, Enejosa, Jeffrey, Lefebvre, Eric, Feinberg, Judith
Publicado 2016

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insuf...

por Fleischmann, Roy M, Genovese, Mark C, Enejosa, Jeffrey V, Mysler, Eduardo, Bessette, Louis, Peterfy, Charles, Durez, Patrick, Ostor, Andrew, Li, Yihan, Song, In-Ho
Publicado 2019

Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy

por Zeng, Xiaofeng, Zhao, Dongbao, Radominski, Sebastiao C., Keiserman, Mauro, Lee, Chang K., Meerwein, Sebastian, Enejosa, Jeffrey, Sui, Yunxia, Mohamed, Mohamed‐Eslam F., Park, Won
Publicado 2021

Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program

por Peterfy, Charles G, Strand, Vibeke, Friedman, Alan, Hall, Stephen, Mysler, Eduardo, Durez, Patrick, Baraliakos, Xenofon, Enejosa, Jeffrey V, Shaw, Tim, Li, Yihan, Chen, Su, Song, In-Ho
Publicado 2021

Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program

por Conaghan, Philip G., Mysler, Eduardo, Tanaka, Yoshiya, Da Silva-Tillmann, Barbara, Shaw, Tim, Liu, John, Ferguson, Ryan, Enejosa, Jeffrey V., Cohen, Stanley, Nash, Peter, Rigby, William, Burmester, Gerd
Publicado 2021

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

por Cohen, Stanley B, van Vollenhoven, Ronald F, Winthrop, Kevin L, Zerbini, Cristiano A F, Tanaka, Yoshiya, Bessette, Louis, Zhang, Ying, Khan, Nasser, Hendrickson, Barbara, Enejosa, Jeffrey V, Burmester, Gerd R
Publicado 2021

Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis

por Fleischmann, Roy M, Blanco, Ricardo, Hall, Stephen, Thomson, Glen T D, Van den Bosch, Filip E, Zerbini, Cristiano, Bessette, Louis, Enejosa, Jeffrey, Li, Yihan, Song, Yanna, DeMasi, Ryan, Song, In-Ho
Publicado 2021